Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes. Goverover Y, Chiaravalloti N. Mult Scler 2023;29:1064-1065.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Goverover Y, Chiaravalloti N. Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes. Mult Scler 2023;29:1064-1065.
PMID: 37489563